{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-24-006057","form_type":"8-K","ticker":"ALGS","cik":"0001799448","company_name":"Aligos Therapeutics, Inc.","filed_at":"2024-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.674069+00:00","generated_at":"2026-05-30T04:43:14.283034+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Aligos Q3 net loss $19.3M; MASH drug shows up to 46.2% liver fat reduction","bullets":["Net loss of $19.3M ($3.07 per share) vs $18.0M ($10.37 per share) in Q3 2023.","Cash & investments $74.9M, down from $135.7M at Dec 31, 2023; runway through end of 2025.","MASH candidate ALG-055009 achieved placebo-adjusted median relative liver fat reduction up to 46.2% at Week 12; favorable tolerability.","CHB candidate ALG-000184 progressing to Phase 2 next year; FDA and China NMPA agree on primary endpoint.","COVID protease inhibitor ALG-097558 to begin externally funded clinical studies in 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-24-006057","json":"https://secwatch.observer/filing/0001171843-24-006057.json","markdown":"https://secwatch.observer/filing/0001171843-24-006057.md","text":"https://secwatch.observer/filing/0001171843-24-006057.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1799448/000117184324006057/0001171843-24-006057-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1799448/000117184324006057/f8k_110624.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T04:43:14.283034+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}